On May 18, 2017 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting to be held June 2 to 6, 2016 in Chicago, Ill (Press release, Myriad Genetics, MAY 18, 2017, View Source [SID1234519220]). Abstracts of the Company’s presentations are currently available at: abstracts.asco.org

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

“We look forward to presenting important new research at ASCO (Free ASCO Whitepaper) in collaboration with our academic partners, advancing personalized medicine in the field of oncology,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “Our presentations will highlight advances in companion diagnostics, hereditary cancer risk assessment, and prediction of oncologic outcomes, all of which are designed to meaningfully improve clinical care for patients.”

A list of Myriad presentations at ASCO (Free ASCO Whitepaper) 2017 is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #ASCO17.

Title

Author Poster/Abstract Number

Day/Time Myriad Product

Podium Presentation

Evaluation of BRCA1/2 and homologous
recombination defects in ovarian cancer and
impact on clinical outcomes Melinda Yates Abstract 5511 Monday,
June 5,
2017: 8:00-
9:30 a.m.
CDT.
Room
E450ab

myChoice
HRD
Poster Discussion
Quantifying Gender Ascertainment Bias in
Hereditary Cancer Testing

Anthony Chen Abstract 6516
Poster Board
338 Monday,
June 5,
2017: 1:15-
4:45 p.m.
and 4:45-
6:00 p.m.
CDT. Myriad
myRisk
Poster Presentations
Expanded Yield of Multiplex Panel Testing in
Fully Accrued Prospective Trial

Performance of Mutation Risk Prediction
Models in a Racially Diverse Multi-Gene Panel
Testing Cohort

Gregory Idos Abstract 1525
Poster Board
183

Abstract 1523
Poster Board
181

Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT. Myriad
myRisk
Development and Validation of a Residual Risk
Score to Predict Breast Cancer Risk in
Unaffected Women Negative for Mutations on a
Multi-Gene Hereditary Cancer Panel

Elisha Hughes Abstract 1579
Poster Board
237 Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT. Myriad
myRisk
Safety of Multiplex Gene Testing for Inherited
Cancer Risk in a Fully Accrued Prospective
Trial Allison Kurian Abstract 1576
Poster Board
234 Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT.

Myriad
myRisk
Multi-Gene Hereditary Cancer Testing among
Men with Breast Cancer Krystal Brown Abstract 1532
Poster Board
190 Monday,
June 5,
2017: 1:15-
4:45 p.m. CDT. Myriad
myR